This small-cap Pharma Stock, engaged in manufacturing and exporting pharmaceutical products, offering a wide range of formulations across various therapeutic categories in domestic and international markets, jumped 13 percent after the company reported March quarterly results with a 139 percent YoY increase in net profit.
With a market capitalization of Rs. 1,916.66 crores, the share of Syncom Formulations (India) Limited has reached an intraday high of Rs. 21.33 per equity share, rising nearly 12.68 percent from its previous day’s close price of Rs. 18.93. Since then, the stock has retreated and is currently trading at Rs. 20.39 per equity share.
Q4 FY25 Result Walkthrough
Coming into the quarterly results of Syncom Formulations (India) Limited, the company’s consolidated revenue from operations increased by 99.65 percent YOY, from Rs. 74.57 crore in Q4 FY24 to Rs. 148.88 crore in Q4 FY25, and grew by 16.74 percent QoQ from Rs. 127.53 crore in Q3 FY25.
Syncom Formulations (India) Limited generated 97.93 percent of its revenue from pharmaceutical drugs and formulations, 1.37 percent from trading of commodities, and 0.70 percent from renting of property in Q4 FY25.
In Q4 FY25, Syncom Formulations (India) Limited’s consolidated net profit increased by 139.05 percent YOY, reaching Rs. 17.69 crore compared to Rs. 7.40 crore during the same period last year. As compared to Q3 FY25, the net profit has increased by 36.08 percent, from Rs. 13 crore. The basic earnings per share increased by 60 percent and stood at Rs. 0.16 as against Rs. 0.10 recorded in the same quarter in the previous year, 2024.
FY25 Result: Syncom Formulations (India) Limited’s revenue has increased from Rs. 263.38 crore in FY24 to Rs. 465.01 crore in FY25, which is a growth of 76.55 percent. The net profit has also grown by 95.30 percent, from Rs. 25.31 crore in FY24 to Rs. 49.43 crore in FY25.
Syncom Formulations (India) Limited was established in 1989 and is a prominent Indian pharmaceutical company engaged in the manufacturing, trading, and export of a wide range of pharmaceutical products.
The company has a manufacturing facility in Pithampur, near Indore, Madhya Pradesh. The company offers over 300 formulations and has more than 400 registered products. It operates in over 15 countries, supplying a wide range of pharmaceutical products globally.
Syncom’s product portfolio includes tablets, capsules, syrups, injections, ointments, inhalers, and herbal medicines. These cover various therapeutic areas like antibiotics, pain relief, cardiac care, antifungals, antimalarials, gastrointestinal treatments, and nutritional supplements, offering healthcare solutions across multiple medical needs.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
